The regulatory agency supports Auris’ plan to conduct multiple doses of AM-201 in a Phase 1 trial with healthy volunteers. The drug is in development to address negative side effects from an antipsychotic medication, olanzapine.
The post Auris Medical Shares Positive FDA Meeting Results appeared first on Investing News Network.
Original Article: Auris Medical Shares Positive FDA Meeting Results